Fusion proteins against sialosylated glycosphingolipids and sialated glycoproteins and uses thereof
AssigneeOn. Target Molecules Biotech Inc.
InventorFrancis V A Fernandes
Life of this patent
Estimating the term…
Abstract
The present invention relates to the fusion proteins against a glycocalyx, found to be associated with several human post-translational modified proteins linked to cancer cell lines. The fusion proteins of the present invention are able to bind only to sialylated glycosphingolipids and sialylated glycoproteins and well as their independent constituents the monosaccharide sugars such as neu5ac, galnac and gal that constitute the glycocalyx. The products claimed can be used for diagnosis and treatment of various cancers. Apoptosis via Caspase 3 occurs in cancer cells when the fusion protein bound to targets is sequestered in lysosomes. The fusion protein is not seen in any other organelle of the cell except for lysosomes.
Claims27
A fusion protein comprising:
- (i) a first binding domain comprising:
- (a) a first variable heavy domain (VH1) having a sequence comprising:
- (i) a vhCDR1 having at least 90% identity to SEQ ID NO:
- 4;
- (ii) a vhCDR2 having at least 90% identity to SEQ ID NO:
- 5;
- and
- (iii) a vhCDR3 having at least 90% identity to SEQ ID NO:
- 6;
- and
- (b) a first variable light domain (VL1) having a sequence comprising:
- (i) a vlCDR1 having at least 90% identity to SEQ ID NO:
- 7;
- (ii) a vlCDR2 having at least 90% identity to SEQ ID NO:
- 8;
- and
- (iii) a vlCDR3 having at least 90% identity to SEQ ID NO:
- 9;
- and
- (ii) a second binding domain comprising:
- (a) a second variable heavy domain (VH2) having a sequence comprising:
- (i) a vhCDR1 having at least 90% identity to SEQ ID NO:
- 10;
- (ii) a vhCDR2 having at least 90% identity to SEQ ID NO:
- 11;
- and
- (iii) a vhCDR3 having at least 90% identity to SEQ ID NO:
- 12;
- and
- (b) a second variable light domain (VL2) comprising:
- (i) a vlCDR1 comprising at least 90% identity to SEQ ID NO:
- 13;
- (ii) a vlCDR2 comprising at least 90% identity to SEQ ID NO:
- 14;
- and
- (iii) a vlCDR3 comprising at least 90% identity to SEQ ID NO:
- 15;
- and
- (iii) a human Fc domain (Fc);
- wherein VH1 and VL1 are connected by a first linker (L1) and VH2 and VL2 are connected by a second linker (L2).
-8. (canceled)
-13. (canceled)
-18. (canceled)
A fusion protein comprising:
- a first binding domain;
- (b) a second binding domain;
- and
- (c) a human Fc domain (Fc);
- wherein each of the first and second binding domains selectively bind to Neu5Acα2-3Galβ1-3GalNAcα-R.
(canceled)
(canceled)
-28. (canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.